昂利康(002940.SZ)擬3245萬元收購海西聯合藥業33.80%股權
格隆匯 12 月 2日丨昂利康(002940.SZ)公佈,此次交易是公司在基於與海西聯合藥業聯合研發七氟烷吸入劑和地氟烷吸入劑的前提下,為進一步優化產業鏈佈局,穩定製劑原料來源,挖掘新的潛在盈利增長點,促進公司快速、高質量發展,擬與明溪縣創新醫藥投資企業(有限合夥)(“創新醫藥”)、明溪海闊醫藥投資企業(有限合夥)(“海闊醫藥”)、明溪縣晴川醫藥投資企業(有限合夥)(“晴川醫藥”)、朱吉洪、黃傑(以上各方以下統稱“交易對方”)簽署相應的《股權轉讓協議》,受讓交易對方合計持有的海西聯合藥業33.80%的股權(對應的認繳出資額為3245萬元),根據雙方協商一致的結果,上述股權轉讓價款為人民幣3245萬元(含税)。
通過此次收購部分股權,一方面公司未來七氟烷吸入劑和地氟烷吸入劑的生產能擁有較為穩定原料供應渠道,初步形成“原料+製劑”一體化的產業格局,另一方面,通過持有部分股權,也能夠享有海西聯合藥業未來在原料藥項目上的部分收益,形成新的盈利增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.